Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials

Optimizing Cholesterol Treatment in Patients With Muscle Complaints

(2017) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intensive LDL-cholesterol lowering therapy and neurocognitive function

(2017) Maciej Banach et al.   PHARMACOLOGY & THERAPEUTICS

Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data

(2016) Lisandro D. Colantonio et al.   CARDIOVASCULAR DRUGS AND THERAPY

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

(2016) Paul M Ridker et al.   EUROPEAN HEART JOURNAL

Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement

(2016) Maciej Banach et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Interpretation of the evidence for the efficacy and safety of statin therapy

(2016) Rory Collins et al.   LANCET

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia

(2015) Christie M. Ballantyne et al.   AMERICAN JOURNAL OF CARDIOLOGY

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Archives of Medical Science

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association between trajectories of statin adherence and subsequent cardiovascular events

(2015) Jessica M. Franklin et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Statins in Chronic Kidney Disease: Cardiovascular Risk and Kidney Function

(2014) Prakash C. Deedwania   POSTGRADUATE MEDICINE

Discontinuation of Statins in Routine Care Settings

(2013) Huabing Zhang et al.   ANNALS OF INTERNAL MEDICINE

Adverse events of statin–fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials

(2013) Qiang Geng et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

(2013) Kevin Fitzgerald et al.   LANCET

Statin Wars: The Heavyweight Match-Atorvastatin versus Rosuvastatin for the Treatment of Atherosclerosis, Heart Failure, and Chronic Kidney Disease

(2013) James J. DiNicolantonio et al.   POSTGRADUATE MEDICINE

Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels

(2012) Clapton S. Dias et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients

(2010) P. Costet et al.   ATHEROSCLEROSIS

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

(2010) Greg Welder et al.   JOURNAL OF LIPID RESEARCH

The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis

(2009) Philippa J. Delahoy et al.   CLINICAL THERAPEUTICS

Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates

(2008) J. Ducobu et al.   ACTA CARDIOLOGICA

Statin discontinuation: an underestimated risk?

(2008) Konstantinos Tziomalos et al.   CURRENT MEDICAL RESEARCH AND OPINION

PCSK9: a convertase that coordinates LDL catabolism

(2008) Jay D. Horton et al.   JOURNAL OF LIPID RESEARCH

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

(2008) M. Frank-Kamenetsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA